STRS Ohio’s Elevation Oncology ELEV Stock Holding History

STRS Ohio’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,700	Closed	-$5.82K	–	1929
2024 Q3	$5.82K	Hold	9,700	–	–	﹤0.01%	1948
2024 Q2	$26.2K	Buy	+9,700	New	+$36.5K	﹤0.01%	1871

Other funds holding ELEV

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio's ELEV Position: Q4 2024 in Review

STRS Ohio sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 9,700 shares — an estimated $5.82K sold.

STRS Ohio first reported a position in ELEV in Q2 2024 and held it in 2 quarters. The position peaked at $26.2K in Q2 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

STRS Ohio reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
STRS Ohio sold 9,700 Elevation Oncology shares in Q4 2024, an estimated $5.82K.
STRS Ohio first reported a position in Elevation Oncology in Q2 2024 and held it in 2 quarters.
STRS Ohio's Elevation Oncology position peaked at $26.2K in Q2 2024.
71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on STRS Ohio's 13F filing for Q4 2024, filed 28 May 2025.